- Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug programmes in obesity, type 2 diabetes, and cardiovascular disease
- Expanded collaboration includes near-term payments totalling up to 190 million US dollars, while Valo is eligible to receive milestone payments of approximately 4.6billion dollars, plus R&D funding and potential royalty payments
Bagsværd, Denmark and Lexington, Massachusetts, US, 8 January 2025 - Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo's extensive human dataset and computation powered by artificial intelligence (AI).
The companies originally partnered in September 2023 in an agreementthat allowed for the development of up to 11 drug programmes, primarily focused on cardiovascular disease, through which Valo was eligible to receive up to 2.7 billion US dollars in milestone payments, plus R&D funding and potential royalty payments.
Under the terms of the expanded agreement, Valo is entitled to receive an upfront payment, equity investment, and a potential near-term milestone payment, totalling 190 million dollars, and is now eligible to receive milestone payments for up to 20 drug programmes, an addition of 9 new drug programmes, totalling approximately 4.6 billion dollars, plus R&D funding and potential royalty payments.
The expanded collaboration will continue to leverage the capabilities of Valo's Opal Computational Platform, as well as key joint capabilities in human data and genetics with Novo Nordisk's expertise in cardiometabolic diseases.
"We are very pleased with the progress we have made together with Valo during the first year of our collaboration, and we are excited to expand the scope to put a stronger focus on obesity and type 2 diabetes in addition to cardiovascular disease," said Marcus Schindler, executive vice president and chief scientific officer of Novo Nordisk. "We have already begun to realize the potential of combining the capabilities of Valo and Novo Nordisk to advance multiple AI-powered, human-centric programmes, and we believe this partnership will help Novo Nordisk fulfil our ambition to expand the number of new drug programmes we bring to the clinic."
The collaboration has already led to the identification of several novel targets that may form the basis of differentiated cardiometabolic drug programmes, and the companies are actively working on multiple small molecule preclinical drug discovery programmes.
"We are excited to build off our early progress with Novo Nordisk, a global leader in obesity and diabetes therapeutics, especially given the renaissance moment in the treatment of cardiometabolic diseases. This level of investment is a testament to our close partnership in deploying human-centric artificial intelligence to rapidly discover and develop novel cardiovascular and metabolic disease therapeutics," said Brian Alexander, CEO of Valo Health and CEO-Partner, Flagship Pioneering. "The partnership fully leverages the Opal Computational Platform by seeking to identify novel therapeutic targets in large real-world patient datasets, validate those targets using human preclinical models, and develop therapeutics against those targets with human-centric AI small molecule design."
The expanded collaboration allows for a deeper partnership between the two companies, with activities that span the entire drug discovery continuum. Novo Nordisk and Valo plan to continue working closely together to derive novel insights from human genetic and longitudinal patient data at the intersection of obesity, type 2 diabetes, and cardiovascular disease.
About Valo Health
Valo Health, Inc is leveraging artificial intelligence.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, X, LinkedIn and YouTube.
Contacts for further information
| Novo Nordisk Media: | |
| Ambre James-Brown +45 3079 9289 abmo@novonordisk.com (mailto:abmo@novonordisk.com) | Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com (mailto:lzsk@novonordisk.com) |
| Novo Nordisk investors: | |
| Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com (mailto:jrde@novonordisk.com) | David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com (mailto:dhel@novonordisk.com) |
| Sina Meyer +45 3075 6656 azey@novonordisk.com (mailto:azey@novonordisk.com) | Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com (mailto:idmg@novonordisk.com) |
| Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com (mailto:fptr@novonordisk.com) | |
| Valo Health Media: | |
| press@flagshippioneering.com (mailto:press@flagshippioneering.com)
| |
| Valo Health Investors: | |
| ir@valohealth.com (mailto:ir@valohealth.com) |
Attachment
- PR250108-Valo-expansion (https://ml-eu.globenewswire.com/Resource/Download/5b89a897-0352-4dc0-af2e-7a4cb45d9d95)
